Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

View all →   RSSRecent Releases
Apr 20, 2018 Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018
Apr 16, 2018 Celldex's METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 7, 2017 Form 10-Q View HTML View PDF 375.0 KB Add to Briefcase
Mar 7, 2018 Form 10-K View HTML View PDF 1.6 MB Add to Briefcase
Add to Briefcase = add file to Briefcase